Abstract 1557P
Background
Liver metastasis (LM) frequently occurs in patients with advanced gastric cancer; yet our understanding of the underlying salient biology is preliminary. Here, we performed single-cell RNA-seq in two patients with LM of gastric cancer to explore the initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer.
Methods
Single cell RNA sequencing was performed on tissues from LM of gastric cancer. Also, we downloaded the single-cell RNA-seq of hepatocellular carcinoma (HCC) and primary gastric cancer from GEO database. Seurat were applied to sort single-cell RNA-seq of LM in gastric cancer and primary gastric cancer into different clusters via feature dimension reduction and then we investigated their expression profiling, stemness initiating and enrichment pathways. Furthermore, CellChat and monocle2 were used to explore the cellular communication and regulatory network of liver metastatic microenvironment.
Results
The transcriptomes of 13305, 26373, 20207 single cells among LM of gastric cancer, HCC, and primary gastric cancer were extracted respectively. There were 14 clusters divided into epithelial cells of liver metastasis single cells. Differential gene analyses and ratio analyses in LM and corresponding primary cancers groups showed that C10 and C12 might be the LM initiating cells clusters. And they were both enriched in the positive regulation of cell migration. SOX6+ MMP7+ epithelial cells might be the LM initiating cells in gastric cancer. Cell communication and inverse temporal analysis showed that SEPP1+ macrophage and CXCL2+ cancer associated fibroblasts (CAFs) might regulate metastatic microenvironment, of which promoted cancer stem cells migration.
Conclusions
The initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer have been investigated in this study, which provided a further understanding of the potential biological mechanisms of LM in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21